Featured Press Releases

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

  • 15 Aug 2024

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection...

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

PureWay and PPSWG Form New Partnership to Transform Pharmaceutical Waste Management in the U.S.

PureWay and PPSWG Form New Partnership to Transform Pharmaceutical Waste Management in the U.S.

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

  • CollPlant
  • 24 Feb 2026
With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

  • Bruker Corporation
  • 24 Feb 2026
SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

  • Clarity Pharmaceuticals
  • 23 Feb 2026
PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

  • PureTech Health plc
  • 20 Feb 2026
ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

  • Merck & Co., Inc.
  • 19 Feb 2026
Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.